Sandhya Bangaru

Sandhya Bangaru

Auto-generated profile, based on publicly available information

Sandhya Bangaru

Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2020 in Science
Verified
Journal Article
Open access
PDF file
SBSandhya Bangaru
Sandhya Bangaru
GOGabriel Ozorowski
Gabriel Ozorowski
HTHannah L. Turner
Hannah L. Turner
AAAleksandar Antanasijevic
Aleksandar Antanasijevic
DHDeli Huang
Deli Huang
AWAndrew Ward
Andrew Ward
Structure of a vaccine candidate: Much effort is being targeted at developing vaccines that will provide protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A trimeric spike protein that decorates the virus is a primary target of the host immune system and the focus of vaccine development. Bangaru et al. present the structure of a leading vaccine candidate: a full-length spike protein with some modifications aimed at enhancing stability that is formulated in polysorbate 80 detergent. The study confirms that the full-length immunogen is in a stable prefusion conformation and provides a basis for understanding immune responses to the vaccine. Science , this issue p. 1089

1 October 2020 in Cell Reports
Verified
Journal Article
Open access
NWNicholas C. Wu
Nicholas C. Wu
MYMeng Yuan
Meng Yuan
Hejun LiuHejun Liu
Hejun Liu
CLChang-Chun D. Lee
Chang-Chun D. Lee
XZXueyong Zhu
Xueyong Zhu
IWIan A. Wilson
Ian A. Wilson
IGHV3-53-encoded neutralizing antibodies are commonly elicited during SARS-CoV-2 infection and target the receptor-binding domain (RBD) of the spike (S) protein. Such IGHV3-53 antibodies generally have a short CDR H3 because of structural constraints in binding the RBD (mode A). However, a small subset of IGHV3-53 antibodies to the RBD contain a longer CDR H3. Crystal structures of two IGHV3-53 neutralizing antibodies here demonstrate that a longer CDR H3 can be accommodated in a different binding mode (mode B). These two classes of IGHV3-53 antibodies both target the ACE2 receptor binding site, but with very different angles of approach and molecular interactions. Overall, these findings emphasize the versatility of IGHV3-53 in this common antibody response to SARS-CoV-2, where conserved IGHV3-53 germline-encoded features can be combined with very different CDR H3 lengths and light chains for SARS-CoV-2 RBD recognition and virus neutralization.

20 October 2021 in Science Translational Medicine
Verified
Journal Article
Open access
HCHyeseon Cho
Hyeseon Cho
KGKristina Kay Gonzales-Wartz
Kristina Kay Gonzales-Wartz
DHDeli Huang
Deli Huang
MYMeng Yuan
Meng Yuan
MPMary Peterson
Mary Peterson
JTJoshua Tan
Joshua Tan
Bispecific antibodies targeting multiple regions of the SARS-CoV-2 spike protein comparably neutralize variants of concern and wild-type virus.

6 May 2022 in Science Advances
Verified
Journal Article
Open access
SBSandhya Bangaru
Sandhya Bangaru
AAAleksandar Antanasijevic
Aleksandar Antanasijevic
NKNurgun Kose
Nurgun Kose
LSLeigh M. Sewall
Leigh M. Sewall
AJAbigail Jackson
Abigail Jackson
AWAndrew Ward
Andrew Ward
Preexisting immunity against seasonal coronaviruses (CoVs) represents an important variable in predicting antibody responses and disease severity to severe acute respiratory syndrome CoV-2 (SARS-CoV-2) infections. We used electron microscopy–based polyclonal epitope mapping (EMPEM) to characterize the antibody specificities against β-CoV spike proteins in prepandemic (PP) sera or SARS-CoV-2 convalescent (SC) sera. We observed that most PP sera had antibodies specific to seasonal human CoVs (HCoVs) OC43 and HKU1 spike proteins while the SC sera showed reactivity across all human β-CoVs. Detailed molecular mapping of spike-antibody complexes revealed epitopes that were differentially targeted by preexisting antibodies and SC serum antibodies. Our studies provide an antigenic landscape to β-HCoV spikes in the general population serving as a basis for cross-reactive epitope analyses in SARS-CoV-2–infected individuals.

4 December 2020 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Nicholas WuNicholas Wu
Nicholas Wu
MYMeng Yuan
Meng Yuan
SBSandhya Bangaru
Sandhya Bangaru
DHDeli Huang
Deli Huang
XZXueyong Zhu
Xueyong Zhu
IWIan A. Wilson
Ian A. Wilson
Epitopes that are conserved among SARS-like coronaviruses are attractive targets for design of cross-reactive vaccines and therapeutics. CR3022 is a SARS-CoV neutralizing antibody to a highly conserved epitope on the receptor binding domain (RBD) on the spike protein that is able to cross-react with SARS-CoV-2, but with lower affinity. Using x-ray crystallography, mutagenesis, and binding experiments, we illustrate that of four amino acid differences in the CR3022 epitope between SARS-CoV-2 and SARS-CoV, a single mutation P384A fully determines the affinity difference. CR3022 does not neutralize SARS-CoV-2, but the increased affinity to SARS-CoV-2 P384A mutant now enables neutralization with a similar potency to SARS-CoV. We further investigated CR3022 interaction with the SARS-CoV spike protein by negative-stain EM and cryo-EM. Three CR3022 Fabs bind per trimer with the RBD observed in different up-conformations due to considerable flexibility of the RBD. In one of these conformations, quaternary interactions are made by CR3022 to the N-terminal domain (NTD) of an adjacent subunit. Overall, this study provides insights into antigenic variation and potential cross-neutralizing epitopes on SARS-like viruses.

2 August 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SZSeth J. Zost
Seth J. Zost
JDJinhui Dong
Jinhui Dong
IGIuliia M. Gilchuk
Iuliia M. Gilchuk
PGPavlo Gilchuk
Pavlo Gilchuk
NTNatalie Thornburg
Natalie Thornburg
JCJames E. Crowe
James E. Crowe
Broadly reactive antibodies targeting the influenza A virus hemagglutinin (HA) head domain are thought to be rare and to require extensive somatic mutations or unusual structural features to achieve breadth against divergent HA subtypes. Here we describe common genetic and structural features of protective human antibodies from several individuals recognizing the trimer interface (TI) of the influenza A HA head, a recently identified site of vulnerability. We examined the sequence of TI-reactive antibodies, determined crystal structures for TI antibody–antigen complexes, and analyzed the contact residues of the antibodies on HA to discover common genetic and structural features of TI antibodies. Our data reveal that many TI antibodies are encoded by a light chain variable gene segment incorporating a shared somatic mutation. In addition, these antibodies have a shared acidic residue in the heavy chain despite originating from diverse heavy chain variable gene segments. These studies show that the TI region of influenza A HA is a major antigenic site with conserved structural features that are recognized by a common human B cell public clonotype. The canonical nature of this antibody–antigen interaction suggests that the TI epitope might serve as an important target for structure-based vaccine design.